US FDA grants orphan drug designation to Imviva Biotech’s CTD402 for the treatment of T-cell leukaemia and lymphoma: Boston Friday, January 30, 2026, 17:00 Hrs [IST] Imviva Biot ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...
FDA approved Novo Nordisk’s oral Wegovy pill for obesity and cardiovascular risk reduction, followed by a successful U.S. launch. The company announced plans to reduce its workforce by 9,000 roles as ...
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...
Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...
CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best strong buy stocks to invest in under $5. AbCellera Biologics Inc.
Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...
Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease ...
Hydrogen powertrain developer ZeroAvia has finally broken its silence on the sweeping redundancies made by the company in recent weeks that have seen around half of its workforce culled on the back of ...
Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient ...
A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results